J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso By Angus Liu Mar 26, 2025 11:45am Johnson & Johnson AstraZeneca Tagrisso EGFR-mutated lung cancer ...

Key Takeaways Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for ...

Session ID: 2025-08-19:55003fbb2e95159e834223f1 Player Element ID: vjs_video_3 ...

Today, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo Inc) for the treatment of adults with locally advanced or metastatic EGFR -mutated non–small ...

In the pooled population, a range of EGFR mutations was observed, including exon 19 del, exon 21 L858R, exon 20 T790M, exon 18 G719X, exon 21 L861Q, exon 20 ins, and exon 20 C797S.

Patients with EGFR-mutant non-small cell lung cancer (NSCLC) tend to do well on treatments, but eventually their disease may stop responding to therapies, highlighting a need for more treatments that ...

The rate of eGFR decline was –2.78 mL/min/1.73 m² during the first 3 months after SGLT2 inhibitor initiation and stabilized to –0.07 mL/min/1.73 m² per 90 days during months 3 through 12.

FDA Grants Breakthrough Therapy Designation to sac-TMT for Certain Patients With Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations ...

In a model, baseline predictors for experiencing a larger acute eGFR dip with empagliflozin included older age, higher baseline eGFR, greater albuminuria, higher systolic blood pressure, lower ...

Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech.